ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings Inc (CRBP)

19.90
-0.01
( -0.05% )
업데이트: 23:14:05

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

가격
19.90
매수가
19.90
매도가
20.06
거래량
33,234
19.86 일간 변동폭 20.3446
3.0334 52주 범위 61.90
market_cap
전일 종가
19.91
개장가
20.34
최근 거래 시간
22
@
19.98
마지막 거래 시간
23:14:11
재정 규모
US$ 668,533
VWAP
20.1159
평균 볼륨(3m)
633,414
발행 주식
12,043,940
배당수익률
-
주가수익률
-5.44
주당순이익(EPS)
-3.7
매출
-
순이익
-44.6M

Corbus Pharmaceuticals Holdings Inc 정보

Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune system. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designe... Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune system. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
본부
Dover, Delaware, USA
설립됨
-
Corbus Pharmaceuticals Holdings Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker CRBP. The last closing price for Corbus Pharmaceuticals was US$19.91. Over the last year, Corbus Pharmaceuticals shares have traded in a share price range of US$ 3.0334 to US$ 61.90.

Corbus Pharmaceuticals currently has 12,043,940 shares in issue. The market capitalisation of Corbus Pharmaceuticals is US$239.79 million. Corbus Pharmaceuticals has a price to earnings ratio (PE ratio) of -5.44.

Corbus Pharmaceuticals (CRBP) 옵션 플로우 요약

전체 흐름

약세

순 프리미엄

-6M

Calls / Puts

14.29%

매수 / 매도

60.00%

OTM / ITM

14.29%

Sweeps 비율

0.00%

CRBP 최신 뉴스

기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-1.33-6.2647197362221.2322.218.826771995320.12644676CS
4-30.49-60.50803730950.3956.9317133341622.84622944CS
12-34.2-63.216266173854.161.91763341432.51536365CS
26-19.69-49.734781510539.5961.91743778836.30058359CS
5213.57214.3759873626.3361.93.033445666932.507176CS
156-10.895-35.37911998730.79561.92.11107672611.96721105CS
260-131.3-86.8386243386151.2322.52.11217886460.82356426CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
PEVPhoenix Motor Inc
US$ 0.755
(117.27%)
43.17M
BENFBeneficient
US$ 1.9199
(61.34%)
54.29M
FORDForward Industries Inc
US$ 5.42
(54.86%)
6.77M
ADTXAditxt Inc
US$ 2.87
(47.94%)
29.26M
NCNCnoco noco Inc
US$ 0.1873
(41.25%)
105.39M
UPXIUpexi Inc
US$ 2.34
(-26.88%)
43.06k
ADDColor Star Technology Company Ltd
US$ 0.3291
(-26.87%)
2.55M
ELABElevai Labs Inc
US$ 0.1004
(-23.94%)
13.95M
CETXCemtrex Inc
US$ 1.96
(-23.44%)
1.35M
LSBLakeShore Biopharma Company Ltd
US$ 5.42
(-20.53%)
20.91k
NCNCnoco noco Inc
US$ 0.1873
(41.25%)
105.39M
NVDANVIDIA Corporation
US$ 123.095
(0.20%)
58.06M
SQQQProShares UltraPro Short QQQ
US$ 7.5699
(-1.82%)
54.38M
BENFBeneficient
US$ 1.9199
(61.34%)
54.29M
PEVPhoenix Motor Inc
US$ 0.755
(117.27%)
43.17M

CRBP Discussion

게시물 보기
ZLAZARUS ZLAZARUS 2 주 전
Way oversold!
👍️0
Disquisition Disquisition 2 주 전
UNINHIBITED DUMPING
👍️0
1984ISHERE 1984ISHERE 1 월 전
Might be almost time to put a short on this
👍️0
Monksdream Monksdream 3 월 전
CRBP new 52=week high
👍️0
Monksdream Monksdream 7 월 전
CRBP new 52 week hi
👍️0
Monksdream Monksdream 7 월 전
CRBP new 52 week hi
👍️0
DollarDan DollarDan 7 월 전
Impressive raise today on no news. Anyone know what's up?
👍️0
Candlestick_Ninja Candlestick_Ninja 7 월 전
youtube.com/watch?v=PsaPEHB... WITHIN $2 OF MY $40 TARGET, MODESTLY BULLISH TO $40 STILL BUT PERSONALLY I'M AT A HOLD.
👍️0
DollarDan DollarDan 7 월 전
Up 10% today, Nice!
👍️0
Candlestick_Ninja Candlestick_Ninja 7 월 전
On Track!
👍️0
Candlestick_Ninja Candlestick_Ninja 7 월 전
$33 by Friday, $40 within 1-3 weeks
👍️0
Monksdream Monksdream 8 월 전
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
TheFinalCD TheFinalCD 8 월 전
I covered my short @ $30 to early but im sure the rest of the shorts that held are loving today

https://ih.advfn.com/stock-market/NASDAQ/corbus-pharmaceuticals-CRBP/stock-news/93155846/form-8-k-current-report
👍️0
TheFinalCD TheFinalCD 8 월 전
CRBP 22.22 i got distracted

and didnt buy the dip
👍️0
glenn1919 glenn1919 8 월 전
CRBP................................https://stockcharts.com/h-sc/ui?s=CRBP&p=W&b=5&g=0&id=p86431144783
👍️0
Pt3 Pt3 8 월 전
Nope it going to 100+
👍️0
PINKFISHERMAN PINKFISHERMAN 8 월 전
Timberrrrrrrrr
👍️0
subslover subslover 8 월 전
That is there problem lol
👍️0
trader59 trader59 8 월 전
Automated wash trading. The O/S has been turned over 7X's already, doesn't happen on any stock, and don't care about the 8K. Every share of stock issued and outstanding has, on average, changed hands 7X's today. When they turn the automation off, a lot of folks will be stuck with grossly overpriced stock.
👍️0
subslover subslover 8 월 전
That is a dangerous thing to do with a stock like this that is so unstable. You're lucky you covered it before it ran to 40.00 in the blink of an eye.
👍️0
TheFinalCD TheFinalCD 8 월 전
I SHORTED @ $30 AND COVERED LOWER BUT TRIED RE-SHORTING $38

NO GO

NO MORE SHORTING WITH MY BROKE ASS BROKER


THATS WHAT I HATE ABOUT SHORTING AS OPPOSED TO LONG

YOU CAN GET STUCK AND NOT BE ABLE TO ADD EVEN THOUGH YOU HAVE PLENTY OF MONEY TO DO SO
👍️0
TheFinalCD TheFinalCD 8 월 전
$40 JUST WOW
👍️ 1
subslover subslover 8 월 전
34.74 and halted
👍️0
TheFinalCD TheFinalCD 8 월 전
#MARKET MADNES$$
👍️0
DollarDan DollarDan 8 월 전
I would be up another $800 on my little 51 shares if I had waited. This stock has been down for some time with only little gains and drops here and there. I sold at $14.30 but no since in rebuying now, might catch a falling knife!
👍️0
make it happen make it happen 8 월 전
It's a deficient stock with a R/S and only in phase one...
👍️0
Awl416 Awl416 8 월 전
LOL
👍️0
subslover subslover 8 월 전
What did I tell you about those beings from another universe?
👍️0
TheFinalCD TheFinalCD 8 월 전
CRBO 27.60 HALT UP

OTC zombie market
👍️0
subslover subslover 8 월 전
INSANITY RULES THE MARKET! tell you I miss the good ole OTC now dead in the water :(
👍️0
subslover subslover 8 월 전
INSANITY RULES THE MARKET! tell you I miss the good ole OTC now dead in the water :(
👍️0
TheFinalCD TheFinalCD 8 월 전
20.71 halted up[
👍️0
subslover subslover 8 월 전
Just a bad month, it's all luck, all we do is speculate now we no longer have a real stock market of the past where mathematics = vision works. Now its just a throw of the dice. A worldwide game of Craps. I hear beings from another universe started this :)
👍️0
TheFinalCD TheFinalCD 8 월 전
why do I always sell too early

1 in 100 i sell the top zone

99 way too early
👍️0
DollarDan DollarDan 8 월 전
Darn it! I sold at $14.30 pre market cause I have been down so long. Oh well!
👍️0
subslover subslover 8 월 전
$19.27 halted
👍️0
subslover subslover 8 월 전
As of November 3, 2023, 4,423,683 shares of the registrant’s common stock, $0.0001 par value, were issued and outstanding.
👍️0
TheFinalCD TheFinalCD 8 월 전
of course it just hit 16.20 SMH
👍️0
TheFinalCD TheFinalCD 8 월 전
got the dip 14.04 sold 14.60 for a quick trade

https://dilutiontracker.com/app/search/CRBP?a=dbb88c
👍️0
subslover subslover 8 월 전
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant doses
All assessable nectin-4 positive study participants with mUC and cervical cancer treated at or above this dose demonstrated some level of disease control
No dose limiting toxicities (DLTs) have been observed to-date up to 3.6 mg/kg (cohort 6) with further escalation at 4.5 mg/kg ongoing
No cases of peripheral neuropathy or skin rash have been observed to date
Cohort 6 is the first cohort selected for dose expansion
NORWOOD, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that data from the first-in-human clinical study of CRB-701 (SYS6002) is being presented as a poster by the Company’s development partner CSPC Pharmaceutical Group at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The Phase 1 dose escalation study is being conducted in China and is enrolling participants with metastatic urothelial cancer (mUC) as well as participants with other solid tumors prospectively confirmed to have nectin-4 positive tumors. The study opened for enrollment in January 2023 and data through December 2023 from the first eighteen participants reflective of the first six dose cohorts (0.2-3.6mg/kg) will be shared.

The poster is titled Phase 1 Dose Escalation of SYS6002(CRB-701), a Next Generation Nectin-4 Targeting Antibody Drug Conjugate by DingWei Ye, et al and is being presented today at the poster session between 11:30 am-1pm PST. The poster will also be available on the Corbus website at the start of the poster presentation.

Safety

CRB-701 was well-tolerated with the majority of adverse events being grade one or two and reversible.
No adverse events above grade three were observed.
There have been no dose discontinuations or reductions in the study to date. There has been a singular participant that experienced a temporary dose interruption.
The dose escalation is ongoing at cohort 7 (4.5 mg/kg).
No cases of drug-related peripheral neuropathy or skin rash have been reported to date.
PK

Single dose PK suggested that TAb, ADC and MMAE increase in an approximate dose proportional manner.
No obvious accumulation was observed on cycle 3, day 1.
When compared to the exposures achieved with enfortumab vedotin (EV) at 1.25 mg/kg Q1W x21 days, CRB-701 (SYS6002) consistently demonstrated lower free MMAE concentrations.
Efficacy

Dose level 5 (2.7 mg/kg) and above represents the predicted therapeutically relevant doses based on allometric scaling.
A mixed tumor population (n=7) receiving doses of 2.7 mg/kg or 3.6 mg/kg demonstrated an ORR of 43% (3 partial responses -2 unconfirmed and one non-responding participant with no-nectin-4 expression) and a disease control rate of 71%.
The longest observed response to date is 11 cycles (~10 months) and ongoing.
All nectin-4 positive mUC and cervical patients at doses ≥ 2.7 mg/kg that were assessable at the time of the December 2023 data-cut off demonstrated levels of disease control and represent the CRB-701 (SYS6002) responsive population to date.
Dr. Yuval Cohen Chief Executive Office of Corbus commented, “CRB-701 with its novel antibody and next generation linker technology, appears to have a differentiated PK profile compared to EV, with a current safety profile devoid of peripheral neuropathy and skin rash, both dose limiting toxicities for EV. This could translate into meaningful benefits for mUC patients and other nectin-4 positive solid tumors such as cervical cancer.”

In reviewing the emerging profile of CRB-701 with one of the preeminent experts in GU cancers, Dr Daniel P. Petrylak M.D., Professor of Medicine and Urology at Yale School of Medicine, Dr. Petrylak shared that “the clinical responses in nectin-4 positive mUC and cervical cancer patients are encouraging and the early clinical safety provides the first evidence that CRB-701 has clinical activity in multiple nectin-4 expressing tumors. This justifies further investigation into the safety and efficacy of this promising compound.”

Dr. Cohen concluded, “as the current clinical study continues to progress in China with our partner CSPC, we at Corbus are looking forward to commencing our clinical study in the US in Q1 2024 under an already open IND. We are grateful to CSPC for the work that has gone into conducting this ongoing study and to the clinicians and study participants."

Dose escalation and expansion are ongoing and additional data presentations are planned for later this year.

About CRB-701
CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer. The Nectin-4 ADC PADCEV® (enfortumab vedotin-ejfv) is approved for use in late metastatic urothelial cancer and recently received an expanded label under an accelerated approval from the Food and Drug Administration for use in combination with KEYTRUDA® for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives o
👍️0
TheFinalCD TheFinalCD 8 월 전
17.10-18.85?
👍️0
TheFinalCD TheFinalCD 8 월 전
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170575841
👍️0
TheFinalCD TheFinalCD 8 월 전
NNHOD 15.50
👍️0
TheFinalCD TheFinalCD 8 월 전
NHOD https://finviz.com/quote.ashx?t=CRBP&ty=c&ta=1&p=d
👍️0
tw0122 tw0122 8 월 전

On January 26, 2024, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release announcing data from the ongoing Phase 1 clinical trial for SYS6002 (CRB-701) conducted by the Company’s development partner, CSPC Pharmaceutical Group, that is being presented at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (the “2024 ASCO GU”) on January 26, 2024. A copy of the press release is attached hereto as Exhibit 99.1.

The Company also updated its presentation used by management to describe its business. A copy of the presentation is furnished as Exhibit 99.2 and is incorporated herein by reference.

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibits 99.1 and 99.2, is being furnished to the Securities and Exchange Commission (the “SEC”), and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
Item 8.01 Other Events.

On January 26, 2024, the Company announced data from the ongoing Phase 1 clinical trial of SYS6002 (CRB-701) conducted by the Company’s development partner, CSPC Pharmaceutical Group, that is being presented at the 2024 ASCO GU on January 26, 2024.

The Phase 1 dose escalation study is being conducted in China and is enrolling patients with metastatic urothelial cancer as well as patients with other solid tumors prospectively confirmed to have nectin-4 positive tumors. The study opened for enrollment in January 2023 and the data presented is through December 2023 from the first eighteen patients reflective of the first six dose cohorts (0.2-3.6 mg/kg).

Safety

CRB-701 was well-tolerated with the majority of adverse events being grade one or two and reversible.

No adverse events above grade three were observed.

There have been no dose discontinuations or reductions in the study to date. There has been a singular participant that experienced a temporary dose interruption.

The dose escalation is ongoing at cohort 7 (4.5 mg/kg).

No cases of drug-related peripheral neuropathy or skin rash have been reported to date.

PK

Single dose PK suggested that TAb, ADC and MMAE increase in a dose proportional manner.

No obvious accumulation was observed on cycle 3, day 1.

When compared to the exposures achieved with enfortumab vedotin (EV) at 1.25 mg/kg Q1W x21 days, CRB-701 (SYS6002) consistently demonstrated lower free MMAE concentrations.

Efficacy

Dose level 5 (2.7 mg/kg and above) represents the predicted therapeutically relevant doses based on allometric scaling.

A mixed tumor population (n=7) receiving doses of 2.7 mg/kg or 3.6 mg/kg demonstrated an ORR of 43% (3 partial responses - 2 unconfirmed and one non responding participant with no-nectin-4 expression) and a disease control rate of 71%.

The longest observed response to date is 11 cycles (~10 months) and ongoing.

All nectin-4 positive mUC and cervical patients at doses ≥ 2.7 mg/kg that were assessable at the time of the December 2023 data-cut off demonstrated levels of disease control and represent the CRB-701 (SYS6002) responsive population to date.
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description
99.1

Press Release dated January 26, 2024
99.2

Investor Presentation
104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




Corbus Pharmaceuticals Holdings, Inc.




Date:
January 26, 2024
By:
/s/ Yuval Cohen



Name: Yuval Cohen
Title: Chief Executive Officer


Exhibit 99.1

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024


Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant doses

All assessable nectin-4 positive study participants with mUC and cervical cancer treated at or above this dose demonstrated some level of disease control

No dose limiting toxicities (DLTs) have been observed to-date up to 3.6 mg/kg (cohort 6) with further escalation at 4.5 mg/kg ongoing

No cases of peripheral neuropathy or skin rash have been observed to date

Cohort 6 is the first cohort selected for dose expansion

Norwood, MA, January 26, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that data from the first-in-human clinical study of CRB-701 (SYS6002) is being presented as a poster by the Company’s development partner CSPC Pharmaceutical Group at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The Phase 1 dose escalation study is being conducted in China and is enrolling participants with metastatic urothelial cancer (mUC) as well as participants with other solid tumors prospectively confirmed to have nectin-4 positive tumors. The study opened for enrollment in January 2023 and data through December 2023 from the first eighteen participants reflective of the first six dose cohorts (0.2-3.6mg/kg) will be shared.

The poster is titled Phase 1 Dose Escalation of SYS6002(CRB-701), a Next Generation Nectin-4 Targeting Antibody Drug Conjugate by DingWei Ye, et al and is being presented today at the poster session between 11:30 am-1pm PST. The poster will also be available on the Corbus website at the start of the poster presentation.

Safety

CRB-701 was well-tolerated with the majority of adverse events being grade one or two and reversible.

No adverse events above grade three were observed.

There have been no dose discontinuations or reductions in the study to date. There has been a singular participant that experienced a temporary dose interruption.

The dose escalation is ongoing at cohort 7 (4.5 mg/kg).

No cases of drug-related peripheral neuropathy or skin rash have been reported to date.

PK

Single dose PK suggested that TAb, ADC and MMAE increase in an approximate dose proportional manner.

No obvious accumulation was observed on cycle 3, day 1.

When compared to the exposures achieved with enfortumab vedotin (EV) at 1.25 mg/kg Q1W x21 days, CRB-701 (SYS6002) consistently demonstrated lower free MMAE concentrations.



Efficacy

Dose level 5 (2.7 mg/kg) and above represents the predicted therapeutically relevant doses based on allometric scaling.

A mixed tumor population (n=7) receiving doses of 2.7 mg/kg or 3.6 mg/kg demonstrated an ORR of 43% (3 partial responses -2 unconfirmed and one non responding participant with no-nectin-4 expression ) and a disease control rate of 71%.

The longest observed response to date is 11 cycles (~10 months) and ongoing.

All nectin-4 positive mUC and cervical patients at doses ≥ 2.7 mg/kg that were assessable at the time of the December 2023 data-cut off demonstrated levels of disease control and represent the CRB-701 (SYS6002) responsive population to date.

Dr. Yuval Cohen Chief Executive Office of Corbus commented, “CRB-701 with its novel antibody and next generation linker technology, appears to have a differentiated PK profile compared to EV, with a current safety profile devoid of peripheral neuropathy and skin rash, both dose limiting toxicities for EV. This could translate into meaningful benefits for mUC patients and other nectin-4 positive solid tumors such as cervical cancer.” In reviewing the emerging profile of CRB-701 with one of the preeminent experts in GU cancers, Dr Daniel P. Petrylack M.D., Professor of Medicine and Urology at Yale School of Medicine, Dr. Petrylak shared that “the clinical responses in nectin-4 positive mUC and cervical cancer patients are encouraging and the early clinical safety provides the first evidence that CRB-701 has clinical activity in multiple nectin-4 expressing tumors. This justifies further investigation into the safety and efficacy of this promising compound.” Dr. Cohen concluded, “As the current clinical study continues to progress in China with our partner CSPC, we at Corbus are looking forward to commencing our clinical study in the US in Q1 2024 under an already open IND. We are grateful to CSPC for the work that has gone into conducting this ongoing study and to the clinicians and study participants."

Dose escalation and expansion are ongoing and additional data presentations are planned for later this year.

About CRB-701
CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer. The Nectin-4 ADC PADCEV® (enfortumab vedotin-ejfv) is approved for use in late metastatic urothelial cancer and recently received an expanded label under an accelerated approval from the Food and Drug Administration for use in combination with KEYTRUDA® for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
👍️0
DollarDan DollarDan 1 년 전
Nice POP today!
👍️0
glenn1919 glenn1919 1 년 전
CRBP................................https://stockcharts.com/h-sc/ui?s=CRBP&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 년 전
CRBP.........................https://www.stockscores.com/charts/charts/?ticker=CRBP
👍️0
europtiger europtiger 2 년 전
The squeeze is on
👍️0
glenn1919 glenn1919 2 년 전
CRBP........................$CRBP 60 million cash and new slide deck just out https://t.co/rmXiR8VV8u https://t.co/F5JlC5oVXk pic.twitter.com/WBaeHVfNie— dough (@semodough) March 16, 2023
👍️0

최근 히스토리

Delayed Upgrade Clock